Abnormal activation of FGFR3 has been recognized to play a cancer‐promoting role in patients with urothelial cancer, especially bladder cancer, in which FGFR3 mutations, rearrangements, and fusions are the most common.247, 248. This evidence concerns the gene FGFR3 and cancer.